Miromatrix Medical Inc. (NASDAQ:MIRO) Short Interest Update

Miromatrix Medical Inc. (NASDAQ:MIRO – Get Rating) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 375,500 shares, an increase of 2,083.1% from the March 15th total of 17,200 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average trading volume of 120,900 shares, the short-interest ratio is currently 3.1 days.

Shares of NASDAQ MIRO traded up $0.12 during trading on Tuesday, reaching $3.84. The company had a trading volume of 5 shares, compared to its average volume of 318,448. Miromatrix Medical has a 52 week low of $2.02 and a 52 week high of $16.52. The company has a current ratio of 12.13, a quick ratio of 12.12 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $3.54.

Miromatrix Medical (NASDAQ:MIRO – Get Rating) last announced its earnings results on Wednesday, March 30th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.12).

Several institutional investors and hedge funds have recently bought and sold shares of MIRO. Millennium Management LLC bought a new stake in shares of Miromatrix Medical during the second quarter worth approximately $654,000. BlackRock Inc. bought a new stake in shares of Miromatrix Medical during the third quarter worth approximately $103,000. Geode Capital Management LLC bought a new stake in shares of Miromatrix Medical during the third quarter worth approximately $71,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Miromatrix Medical during the fourth quarter worth approximately $171,000. Finally, Sweet Financial Partners LLC bought a new stake in shares of Miromatrix Medical during the fourth quarter worth approximately $47,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Miromatrix Medical Company Profile (Get Rating)

Miromatrix Medical Inc engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company also develops organ-derived biological products for various applications, such as soft tissue reinforcement and wound care. It uses its perfusion decellularization/recellularization technology to engineer transplantable organs for the people who need them.

See Also